文献速递前列腺癌

MRI对局限性前列腺癌高强度聚焦超声部分腺体消融术后复发的诊断准确性:系统综述与Meta分析

MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-09-10

该系统综述与Meta分析检索至2024年5月8日,纳入15项研究共1093例接受高强度聚焦超声(HIFU)部分腺体消融(PGA)的局限性前列腺癌患者,其中12项研究进入Meta分析。MRI检测临床显著前列腺癌(csPCa,ISUP≥2)复发的汇总敏感度为0.52(95%CI:0.36-0.68),汇总特异度为0.81(95%CI:0.68-0.91),汇总阳性预测值为0.50(95%CI:0.35-0.65),汇总阴性预测值为0.82(95%CI:0.72-0.90)。

要点

  • MRI检测HIFU PGA后csPCa复发的汇总敏感度为0.52(95%CI:0.36-0.68),汇总特异度为0.81(95%CI:0.68-0.91)。
  • MRI检测csPCa复发的汇总阳性预测值为0.50(95%CI:0.35-0.65),汇总阴性预测值为0.82(95%CI:0.72-0.90)。
  • 3项研究报告了治疗区内诊断效能,敏感度范围为0.42至0.80,特异度范围为0.45至0.97。

核心结论

  • MRI对局限性前列腺癌HIFU部分腺体消融后临床显著复发的诊断准确性在治疗叶内显示诊断效能较低,汇总敏感度为0.52(95%CI:0.36-0.68),汇总特异度为0.81(95%CI:0.68-0.91)。

研究设计与样本

  • 遵循PRISMA指南,检索MEDLINE和Scopus至2024年5月8日,纳入随机对照试验和队列研究,对象为以HIFU PGA作为主要治疗的局限性前列腺癌男性。
  • 共纳入15项研究,包含1093例患者,其中12项研究符合Meta分析条件。
  • 主要结局指标为基于活检结果的MRI检测csPCa(ISUP≥2)的敏感度、特异度、阳性预测值(PPV)和阴性预测值(NPV)。

主要发现

  • MRI检测HIFU PGA后csPCa复发的敏感度范围为0%至89%,汇总敏感度为0.52(95%CI:0.36-0.68)。
  • MRI检测csPCa复发的特异度范围为44%至100%,汇总特异度为0.81(95%CI:0.68-0.91)。
  • 汇总NPV为0.82(95%CI:0.72-0.90),汇总PPV为0.50(95%CI:0.35-0.65)。
  • 3项研究报告了治疗区内诊断效能,敏感度范围为0.42至0.80,特异度范围为0.45至0.97。

关键数值与推荐

  • csPCa定义为ISUP≥2。
  • Meta分析纳入标准为HIFU术后csPCa患者和無csPCa患者均≥5例的研究。

局限性

  • 本综述的局限性包括报告复发部位在治疗叶内或叶外的研究数量少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer remains the most frequently diagnosed cancer among men. High-Intensity Focused Ultrasound (HIFU) has emerged as a thermal ablative technique for partial-gland-ablation (PGA), aiming to minimize collateral damage while maximizing tumor control. Monitoring after HIFU PGA relies on serial PSA testing, multiparametric-MRI, and biopsies. The diagnostic accuracy of MRI for clinically-significant cancer(csPCa) recurrence is challenging. OBJECTIVE: This systematic review and meta-analysis aim to evaluate the accuracy of MRI in detecting early recurrence of localized prostate cancer following HIFU PGA. METHODS: Adhering to PRISMA guidelines, a comprehensive literature search was conducted until May 8th 2024 using MEDLINE and Scopus. The inclusion criteria encompassed randomized controlled trials and cohort studies involving men diagnosed with localized prostate cancer who had as primary treatment HIFU PGA. The primary outcome measures included the sensitivity, specificity, positive-predictive value (PPV), and negative-predictive value (NPV) of MRI for csPCa(ISUP ≥ 2) based on biopsy results. We pooled data from studies with sufficient csPCa and csPCa-free patients (≥5) post HIFU for statistical analysis. RESULTS: Fifteen studies meet the inclusion criteria, encompassing 1093 patients and 12 studies were eligible for meta-analysis. MRI sensitivity in detecting clinically-significant prostate cancer (csPCa) recurrence post HIFU PGA varied widely (0-89%), with a pooled sensitivity of 0.52 (95% CI:0.36-0.68). Specificity ranged from 44% to 100%, with a pooled specificity of 0.81 (95% CI:0.68-0.91). The pooled NPV was 0.82 (95% CI:0.72-0.90), and the pooled PPV was 0.50 (95% CI:0.35-0.65). Three studies reported in-field diagnostic performance with sensitivities ranging from 0.42 to 0.80 and specificities from 0.45 to 0.97. CONCLUSION: MRI accuracy for clinically-significant recurrence after partial gland ablation with HIFU for localized prostate cancer shows low diagnostic performance in the treated lobe with pooled sensitivity of 0.52 (95% CI:0.36-0.68) and specificity of 0.81 (95% CI:0.68-0.91). Limits of this review include the low number of studies reporting about site of recurrence in or out of the treated lobe.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Séguier D, Puech P, Barret E, et al. MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 39256551. doi:10.1038/s41391-024-00885-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。